Nimotuzumab Plus Paclitaxel and Cisplatin as a 1(st)-Line Treatment for Esophageal Cancer: Long Term Follow-up of a Phase II Study

The effect of anti-epidermal growth factor receptor targeted treatment in esophageal squamous cell carcinoma (ESCC) is still unclear. We conducted a prospective phase II study of paclitaxel, cisplatin, and nimotuzumab (TPN) as a first-line treatment for unresectable or metastatic ESCC and the object...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Cancer
Main Authors: Zhang, Xiaodong, Jia, Jun, Lu, Ming, Wang, Xicheng, Gong, Jifang, Li, Jie, Li, Jian, Li, Yan, Zhang, Xiaotian, Lu, Zhihao, Zhou, Jun, Yu, Jing, Sun, Zhiwei, Yang, Ying, Liu, Chuanling, Xiao, Yanjie, Shen, Lin
Formato: Artigo
Idioma:Inglês
Publicado em: Ivyspring International Publisher 2019
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6485235/
https://ncbi.nlm.nih.gov/pubmed/31031851
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7150/jca.28659
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados